|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.46 EUR | +2.28% |
|
+0.31% | +6.95% |
| 24/07 | European Stocks Close Higher Friday; Eurozone Private Sector Expands in July | MT |
| 24/07 | GSK : JP Morgan reiterates its Sell rating | ZD |
| Market Cap | 7.64TCr 10TCr 8.96TCr 8.33TCr 14TCr 9,82200Cr 15TCr 99TCr 39TCr 4,82900Cr 38TCr 37TCr 16,69600Cr | P/E 2026 * |
12.1x | P/E 2027 * | 11.1x |
|---|---|---|---|---|---|
| Enterprise Value | 9.19TCr 12TCr 11TCr 10TCr 17TCr 11,80900Cr 18TCr 1,18900Cr 46TCr 5,80600Cr 46TCr 45TCr 20,07400Cr | EV / Sales 2026 * |
2.71x | EV / Sales 2027 * | 2.49x |
| Free-Float |
86.83% | Yield 2026 * |
3.63% | Yield 2027 * | 3.81% |
Last Transcript: GSK plc
| 1 day | +2.28% | ||
| 1 week | +0.31% | ||
| Current month | -2.90% | ||
| 1 month | -1.75% | ||
| 3 months | -4.67% | ||
| 6 months | +9.24% | ||
| Current year | +6.95% |
| 1 week | 21.84 |  | 22.57 |
| 1 month | 21.84 | | 23.7 |
| Current year | 20.27 | | 26.02 |
| 1 year | 15.78 | | 26.02 |
| 3 years | 14.68 | | 26.02 |
| 5 years | 14.62 | | 27.13 |
| 10 years | 14.62 | | 27.52 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
| Chief Tech/Sci/R&D Officer | - | 01/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 06/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 68 | 01/09/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.28% | +0.31% | - | - | 10TCr | |
| +0.86% | +1.43% | +48.50% | +160.39% | 1,06700Cr | |
| +1.59% | +4.09% | +55.34% | +53.96% | 63TCr | |
| +0.95% | +1.91% | +35.91% | +81.14% | 46TCr | |
| +1.60% | +6.25% | +33.95% | +29.84% | 35TCr | |
| -0.60% | +1.52% | +35.68% | +39.76% | 30TCr | |
| -0.14% | +0.60% | +16.17% | +17.53% | 26TCr | |
| +0.09% | -2.82% | -28.29% | -41.71% | 22TCr | |
| +1.22% | +2.66% | +21.87% | +59.73% | 20TCr | |
| -1.18% | -3.70% | +14.23% | +66.51% | 16TCr | |
| Average | +0.56% | +1.33% | +25.93% | +51.91% | 40.48TCr | |
| Weighted average by Cap. | +0.59% | +1.95% | +35.81% | +77.68% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.39TCr 4.52TCr 3.97TCr 3.69TCr 6.37TCr 4,35600Cr 6.47TCr 44TCr 17TCr 2,14200Cr 17TCr 17TCr 7,40500Cr | 3.57TCr 4.76TCr 4.18TCr 3.89TCr 6.7TCr 4,58100Cr 6.8TCr 46TCr 18TCr 2,25200Cr 18TCr 17TCr 7,78700Cr |
| Net income | 646.82Cr 862.98Cr 757.95Cr 704.88Cr 1.22TCr 83TCr 1.23TCr 8.37TCr 3.27TCr 41TCr 3.24TCr 3.17TCr 1,41300Cr | 692.22Cr 923.55Cr 811.15Cr 754.35Cr 1.3TCr 89TCr 1.32TCr 8.96TCr 3.5TCr 44TCr 3.47TCr 3.39TCr 1,51200Cr |
| Net Debt | 1.55TCr 2.06TCr 1.81TCr 1.69TCr 2.91TCr 1,98800Cr 2.95TCr 20TCr 7.82TCr 98TCr 7.75TCr 7.58TCr 3,37800Cr | 1.25TCr 1.66TCr 1.46TCr 1.36TCr 2.34TCr 1,60300Cr 2.38TCr 16TCr 6.31TCr 79TCr 6.25TCr 6.11TCr 2,72400Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/26/24 | €22.46 | +2.28% | 157 |
| 23/26/23 | €21.96 | -2.10% | 160 |
| 22/26/22 | €22.43 | +2.70% | 92 |
| 21/26/21 | €21.84 | -0.68% | 213 |
| 20/26/20 | €21.99 | -1.79% | 171 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
- GS71 Stock
Select your edition
All financial news and data tailored to specific country editions
